The financial markets have been driven by the coronavirus, Fed policy, government stimulus, and politics up to now, but a change is in order.
We now see an earnings driven market, which will benefit active over passive managers and hard research, which is our forte. We recommend focusing on operating margins as corporations have done a great job navigating through the pandemic cutting costs, using more technology, shifting more functions online, and restructuring operations/supply lines. All of this is occurring faster than we assumed a few months ago when we began focusing on improving operating margins, operating profits, and cash flow.
Not all companies will benefit equally. We expect the larger, well-financed companies with forward-thinking management to significantly increase market share at the expense of small and medium less-financed competitors. Expect many of them to provide dividend hikes, renew buybacks, and make bolt-on acquisitions. Listen closely to the upcoming earnings
SAN LUIS OBISPO, Calif., Oct. 8, 2020 /PRNewswire/ — Mindbody, the leading technology platform for the wellness industry, continues to make strategic investments in its core technology in addition to advancing its product development efforts in the face of an increasingly challenging business environment brought on by the coronavirus. The emphasis on product and technology is in line with Mindbody’s stated direction of being a product led company.
Mindbody, which counts tens of thousands of customers in the fitness, beauty and wellness industries, is in the process of reimagining its core software platform to deliver additional value to the wellness businesses that rely on its integrated software and payments platform to run, market, and grow their businesses.
Regina Wallace-Jones, who was recently promoted to Senior Vice President of Insight and Innovation, leads several critical areas that are powering Mindbody’s future growth.
New York-based decentralized computing network Blockstack which announced its proof of transfer mining algorithm earlier this year has announced that it has now launched Krypton – the third phase of the Stacks 2.0 testnet.
Its next milestone will focus on testing Stacks 1.0-2.0 upgrades with integration and testing with the Bitcoin (BTC) testnet.
Krypton is an important development in Blockstack’s novel mining consensus mechanism Proof-of-Transfer (PoX). This uses Bitcoin to secure an independent blockchain network, called Stacks 2.0.
PoX makes it also possible to reward Stacks token holders with bitcoin BTC, a feature called Stacking. With Stacking, Stacks (STX) token holders lock up STX tokens for a certain amount of time. Doing this helps to secure the network by acting as validators on the network, incentivizing honest behavior on the part of miners.
Developers and miners will be able to interact with the full Proof-of-Transfer mechanism, and users will soon
Independent Data Monitoring Committee recommended on September 30, 2020 that the study continue into Phase 3 based on a positive evaluation of safety and tolerability data from the Phase 2 lead-in
Initial Phase 3 results may be available as early as the end of 2020; results for the primary endpoint are expected in the first quarter of 2021, with current estimates at January 2021
If successful, VIR-7831 has the potential to advance outpatient treatment for COVID-19
Patient enrollment underway; website live at https://vircovid19study.com/
SAN FRANCISCO and LONDON, Oct. 06, 2020 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial – Intent to Care Early) study evaluating VIR-7831 for the early treatment of COVID-19 in patients who are at high risk of hospitalization. VIR-7831 (also known as GSK4182136) is a fully
(Reuters) – Intel Corp on Friday said that it has won a second-phase contract in a project aimed at helping the U.S. military make more advanced semiconductors within the United States.
Under the project, Intel will help the military develop prototypes of chips using its semiconductor packaging technology at factories in Arizona and Oregon. The packaging technology allows pieces of chips called “chiplets” from different providers to be combined into one package, helping cram more features into a smaller finished product while lowering its power consumption.
Intel declined to disclose a dollar figure for its portion of the contract, which is being overseen by the Naval Surface Warfare Center, Crane Division. Intel won part of the first phase of the contract in 2019.
Intel’s work with the Defense Department comes as U.S. officials focus on boosting domestic semiconductor manufacturing in response to the rise of China as
New York, NY–October 1, 2020–A promising new COVID-19 rapid-testing technology platform developed by Rover Diagnostics and Columbia Engineering has been selected by the National Institutes of Health (NIH) to enter Phase 1 of the Rapid Acceleration of Diagnostics (RADx) initiative to support new COVID-19 testing technologies. The affordable, portable, and ultrafast point-of-care Rover platform provides reverse transcription polymerase chain reaction (RT-PCR) results in eight minutes, faster than any other test of its kind, with targeted accuracy to match laboratory-based tests.
Widely used since the 1980s for both clinical and research purposes, RT-PCR has been the gold standard for molecular diagnostic testing for decades. But because traditional PCR requires typically 45 minutes and trained
This sensor builds on the proven Micro Weather Sensor to include fuel moisture, solar radiation, particulate monitoring, and thermal imaging that will improve firefighting efforts.
Torrance ,CA, Sept. 29, 2020 (GLOBE NEWSWIRE) — September29, 2020 – Torrance, CA – Intellisense Systems, Inc., a leading provider of integrated environmental sensing solutions, won Phase II funding to continue development of the Fire Weather Observation Sensor (FWOS) from the United States Department of Agriculture (USDA). The FWOS is a stand-alone, unattended, field-deployable sensor for remote measurements of fire weather-related data. These devices will be placed throughout forests and areas prone to wildfire outbreak and transmit data via satellite from anywhere in the world. This development will integrate new sensing capabilities to the proven Micro Weather Sensor (MWS®) platform, including fuel moisture, solar radiation, particulate monitoring, and thermal imaging.
In 2020, the Western United States experienced a record-setting number of wildfires, which have
New research published in EPJ B reveals that the nature of the boundary at which an antiferromagnet transitions to a state of disorder slightly depends on the geometry of its lattice arrangement.
Calculations involving ‘imaginary’ magnetic fields show how the transitioning behaviours of antiferromagnets are subtly shaped by their lattice arrangements.
Antiferromagnets contain orderly lattices of atoms and molecules, whose magnetic moments are always pointed in exactly opposite directions to those of their neighbours.
These materials are driven to transition to other, more disorderly quantum states of matter, or ‘phases,’ by the quantum fluctuations of their atoms and molecules — but so far, the precise nature of this process hasn’t been fully explored. Through new research published in EPJ B, Yoshihiro Nishiyama at Okayama University in Japan has found that the nature of the boundary at which this transition occurs depends on the geometry of an antiferromagnet’s lattice arrangement.
The MarketWatch News Department was not involved in the creation of this content.
AB Science Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World’s Largest Multiple Sclerosis Research Conference
50% of patients suffering from multiple sclerosis have one of the progressive forms of the disease, for which there is no satisfactory treatment to date
Masitinib, a tyrosine kinase inhibitor developed by AB Science, provides the first clinical evidence that targeting the innate immune system is an effective strategy for the treatment of progressive forms of multiple sclerosis.
AB Science SA (Euronext – FR0010557264 – AB), a pharmaceutical company specialized on the research, development and commercialization of protein kinase inhibitors (PKIs), announced today that it has presented the world’s first key results from its Phase 2B/3 study (AB07002) evaluating its lead product, masitinib, in both progressive forms of multiple sclerosis1 during the 8th Joint Meeting of